Mirum Pharmaceuticals, Inc. Selling, General and Administrative Expense
Mirum Pharmaceuticals, Inc. (MIRM) reported Selling, General and Administrative Expense of $81.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $81.47M, a 28.73% increase year-over-year.
- Mirum Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $96.33M, a 66.93% increase year-over-year.
- Mirum Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $74.13M, a 30.44% increase year-over-year.
- Mirum Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $61.91M, a 22.48% increase year-over-year.
- Mirum Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2025 was $257.03M, a 27.10% increase from fiscal 2024.
- Mirum Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2024 was $202.22M, a 38.62% increase from fiscal 2023.
- Mirum Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2023 was $145.88M, a 63.79% increase from fiscal 2022.
- Mirum Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2022 was $89.07M, a 50.40% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $81.47M 10-Q · filed 2026-08-05 | $177.80M 10-Q · filed 2026-08-05 | $251.93M derived: sum of 3 quarters · filed 2026-08-05 | $313.84M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $96.33M 10-Q · filed 2026-05-06 | $170.46M derived: sum of 2 quarters · filed 2026-05-06 | $232.37M derived: sum of 3 quarters · filed 2026-05-06 | $295.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $74.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $136.04M derived: sum of 2 quarters · filed 2026-02-25 | $199.32M derived: sum of 3 quarters · filed 2026-08-05 | $257.03M 10-K · filed 2026-02-25 |
| 2025-09-30 | $61.91M 10-Q · filed 2025-11-04 | $125.20M derived: sum of 2 quarters · filed 2026-08-05 | $182.90M 10-Q · filed 2025-11-04 | $239.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $63.29M 10-Q · filed 2026-08-05 | $120.99M 10-Q · filed 2026-08-05 | $177.82M derived: sum of 3 quarters · filed 2026-08-05 | $228.37M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $57.71M 10-Q · filed 2026-05-06 | $114.54M derived: sum of 2 quarters · filed 2026-05-06 | $165.08M derived: sum of 3 quarters · filed 2026-05-06 | $214.29M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $56.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $107.38M derived: sum of 2 quarters · filed 2026-02-25 | $156.58M derived: sum of 3 quarters · filed 2026-02-25 | $202.22M 10-K · filed 2026-02-25 |
| 2024-09-30 | $50.55M 10-Q · filed 2025-11-04 | $99.75M derived: sum of 2 quarters · filed 2025-11-04 | $145.39M 10-Q · filed 2025-11-04 | $191.57M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $49.21M 10-Q · filed 2025-08-06 | $94.85M 10-Q · filed 2025-08-06 | $141.03M derived: sum of 3 quarters · filed 2026-02-25 | $177.56M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $45.64M 10-Q · filed 2025-05-07 | $91.82M derived: sum of 2 quarters · filed 2026-02-25 | $128.35M derived: sum of 3 quarters · filed 2026-02-25 | $161.30M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $46.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $82.71M derived: sum of 2 quarters · filed 2026-02-25 | $115.66M derived: sum of 3 quarters · filed 2026-02-25 | $145.88M 10-K · filed 2026-02-25 |
| 2023-09-30 | $36.53M 10-Q · filed 2024-11-12 | $69.48M derived: sum of 2 quarters · filed 2024-11-12 | $99.70M 10-Q · filed 2024-11-12 | $126.16M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $32.95M 10-Q · filed 2024-08-07 | $63.17M 10-Q · filed 2024-08-07 | $89.64M derived: sum of 3 quarters · filed 2025-02-26 | $112.15M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $30.22M 10-Q · filed 2024-05-08 | $56.69M derived: sum of 2 quarters · filed 2025-02-26 | $79.20M derived: sum of 3 quarters · filed 2025-02-26 | $100.17M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $26.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $48.98M derived: sum of 2 quarters · filed 2025-02-26 | $69.95M derived: sum of 3 quarters · filed 2025-02-26 | $89.07M 10-K · filed 2025-02-26 |
| 2022-09-30 | $22.51M 10-Q · filed 2023-11-02 | $43.48M derived: sum of 2 quarters · filed 2023-11-02 | $62.60M 10-Q · filed 2023-11-02 | $81.63M derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-06-30 | $20.97M 10-Q · filed 2023-08-07 | $40.09M 10-Q · filed 2023-08-07 | $59.12M derived: sum of 3 quarters · filed 2024-03-15 | $76.47M derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-03-31 | $19.12M 10-Q · filed 2023-05-04 | $38.15M derived: sum of 2 quarters · filed 2024-03-15 | $55.50M derived: sum of 3 quarters · filed 2024-03-15 | $68.86M derived: sum of 4 quarters · filed 2024-03-15 |
| 2021-12-31 | $19.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $36.39M derived: sum of 2 quarters · filed 2024-03-15 | $49.74M derived: sum of 3 quarters · filed 2024-03-15 | $59.22M 10-K · filed 2024-03-15 |
| 2021-09-30 | $17.35M 10-Q · filed 2022-11-09 | $30.71M derived: sum of 2 quarters · filed 2022-11-09 | $40.19M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $13.35M 10-Q · filed 2022-08-04 | $22.83M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $9.48M 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |